Pakistani American Pharmaceutical Association

Text Box: Page #
Text Box: Federal Limits on Pseudoephedrine-Containing Products

 

Text Box: PAPA’S Members with Eliot Spitzer Attorney General of New York State and a Candidate for the Governor of 
New York State  2006

In March, Congress passed new requirements for the sale of all (single and multi-ingredient)

pseudoephedrine and ephedrine-containing products. The new law (Public Law 109-177) places ephedrine,

pseudoephedrine (PSE), and phenylpropanolamine in a new Controlled Substances Act (CSA) category of

‘scheduled listed chemical products’. Drug products containing ephedrine, PSE, and phenylpropanolamine

are subject to sales restrictions, storage requirements and record keeping requirements. Some of these

requirements, which apply to all sellers of these products, go into effect by April 8th; others require

compliance by September 30, 2006. If your state has more stringent requirements, the stronger requirements

remain in place.

Effective April 8, 2006

3.6 gram daily sales limit

9.0 gram 30-day sales limit

All non-liquid forms must be sold in blister packs (with a few

exceptions)

Mail-service pharmacy must verify patient’s identification

before shipping product

Mail-service pharmacy 7.5 gram 30-day sales limit

Effective by September 30, 2006

Products must be placed behind a counter or in a locked cabinet

Seller must maintain a written or electronic logbook** which

must identify:

• the product name

• the quantity sold

• names and addresses of purchasers

• dates and times of sales

Purchasers must present a photo ID* and sign the logbook

Sellers must self-certify to the U.S. Attorney General that their

sales personnel have been trained as required by regulations (yet

to be promulgated)

7.5 gram 30-day sales limits for mobile sellers (such as kiosks in

airports)

* Logbook and ID requirements do not apply to sales of 60 mg or less of pseudoephedrine.

There are more changes on the horizon. Many of the requirements that go into effect by September 30th will

require promulgation of regulations to address logbook and training requirements and ways to address

privacy issues that could arise with the logbook. Additionally, APhA is working to get confirmation from

the DEA that the regulations do not apply to prescribed products, including prescribed over-the-counter

products. For more information visit www.aphanet.org

 

 

1  2  3  4  5  6  7  8

Page Numbers: